news

Sientra Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

02/01/2019

SANTA BARBARA, Calif., Feb. 01, 2019 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) (“Sientra” or the “Company”), a medical aesthetics company, today announced that on January 31, 2019, the Compensation Committee of the Board of Directors approved equity award grants under the Sientra Inc. Inducement Plan to 39 new employees.

The new employees were granted restricted stock units representing a total of 80,561 shares of common stock. The restricted stock units will vest in time-based installments beginning on the grant date.  In each case, the vesting of shares is contingent upon the recipient’s continued service with the Company through each vesting date.

The grants were made as an inducement that was a material component of each person’s compensation and subsequent acceptance of employment with the Company or joining Sientra’s miraDry subsidiary, and were granted as employment inducement awards pursuant to NASDAQ Listing Rule 5635(c)(4) approved by the Compensation Committee.

About Sientra

Headquartered in Santa Barbara, California, Sientra is a diversified global medical aesthetics company and a leading partner to aesthetic physicians. The Company offers a suite of products designed to make a difference in patients' lives by enhancing their body image, growing their self-esteem, and restoring their confidence. Sientra has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes.   The Company’s Breast Products Segment includes its OPUS™ breast implants, the first fifth generation breast implants approved by the FDA for sale in the United States, its ground-breaking Allox2® breast tissue expander with patented dual-port and integral drain technology,  and BIOCORNEUM® the #1 performing, preferred and recommended scar gel of plastic surgeons[*].  The Company’s miraDry Segment, comprises its miraDry® system, which is approved for sale in over 40 international markets, and is the only non-invasive FDA-cleared device for the permanent reduction of underarm sweat, odor and hair of all colors.

Investor Contacts: 
Neil Bhalodkar
(805) 679-8845
neil.bhalodkar@sientra.com

[*] Data on file

logo_no_tag_2c.jpg

Source: Sientra, Inc.

NASD: SIEN

Stock Quote: NASD

$8.11 -0.23
Volume 425,386
Previous Close 8.34
Intraday High 8.45
Intraday Low 7.99
Pricing delayed 20 minutes
Price Change % Change -2.76% 52 Week High 17.48 52 Week Low 4.78 Today's Open 8.33 Dec 09, 2019 03:36 PM

Investor Contact

Sientra Investor Relations
805-679-8885

script